Sun City, AZ – Researchers at Banner Sun Health Research Institute, in partnership with Boston University, have taken a significant step toward diagnosing chronic traumatic encephalopathy (CTE) in living individuals. The study, published in the Journal of the American Medical Association (JAMA), describes the first use of a blood test to detect advanced CTE, a neurodegenerative disease linked to repeated head impacts.
Study design and key findings
The investigation examined plasma samples from 21 former American football players who had donated their brains to the BU CTE Center Brain Bank after death. By measuring levels of a protein called endogenously cleaved microtubule‑binding region tau (eMTBR‑tau), the researchers identified a clear difference: players with high‑stage CTE showed significantly higher eMTBR‑tau concentrations than those with low‑stage CTE or no CTE. The protein was not elevated in the latter groups.
These results echo recent advances in Alzheimer’s disease, where FDA‑cleared blood tests have transformed diagnosis and clinical trial design. Nicholas Ashton, PhD, co‑senior author and senior director of Banner Health’s Fluid Biomarker Program, said the team is optimistic that a similar breakthrough could occur for CTE.
Expert commentary and cautions
Michael Alosco, PhD, corresponding author and co‑director of clinical research at the BU CTE Center, called the discovery a “game changer,” while emphasizing that the work remains in the discovery phase. He noted the study’s limited sample size and the need for larger, age‑matched control groups before the test can be used clinically.
Both researchers stressed that the blood test is not yet FDA‑approved and should not be used for diagnostic decisions until further validation studies are completed. They recommend that individuals concerned about brain health consult clinicians specializing in neurodegenerative conditions to assess risk factors and explore appropriate care.
Implications for the community
For Sun City residents and the broader Arizona athletic community, the research offers hope that early detection of CTE could eventually lead to targeted treatments and preventive strategies. As more studies replicate these findings, the prospect of routine blood screening for at‑risk athletes may become a reality, potentially reducing the long‑term impact of head injuries on families and local healthcare resources.
In the meantime, the Banner Sun Health Research Institute continues to advance its Fluid Biomarker Program, aiming to translate laboratory discoveries into practical tools that support brain health for all Arizonans.
Original reporting: azfamily KTVK/KPHO Phoenix (news) — read the source article.